
    
      Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety
      of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated
      with Cushing's syndrome, and sub-optimally controlled on basal insulin, with or without
      prandial insulin and/or maximally-tolerated doses of metformin.
    
  